Newsroom | 94886 results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025. One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to purchase 20,600 shares of Adicet’s common stock with an exercise price of $0.65 per share, the closing price of...

DUBLIN--(BUSINESS WIRE)--The "CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking treatment modality, offering new hope for patients with relapsed or refractory multiple myeloma (RRMM). Building upon traditional treatments such as autologous stem cell transpl...

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM     1. Details of the p...

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of November 27, 2025...

TORONTO, Ontario--(BUSINESS WIRE)--Celltrion, Inc. today announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea.1 “Today’s approval lays a solid foundation for Celltrion’s expansion into the Canadian ophthalmology market and represents a significant milestone in diversifying the company’s portfolio,” said Jungyong Shin, Managing Director at Celltrion...

TORONTO, Ontario--(BUSINESS WIRE)--Celltrion, Inc. annoncé aujourd'hui que Santé Canada a approuvé l'Eydenzelt®, un biosimilaire référençant l'Eylea® (aflibercept 2mg), en flacon et en seringue préremplie, pour le traitement de toutes les indications approuvées pour l'Eylea.1 « L’approbation d’aujourd’hui jette des bases solides pour l’expansion de Celltrion sur le marché canadien de l’ophtalmologie et représente une étape importante dans la diversification du portefeuille de la société », décl...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- BeOne Medicines（Nasdaq：ONC、HKEX：06160、SSE：688235）は、グローバルに展開するオンコロジー企業として、次世代BCL-2阻害薬のソンロトクラックスについて、米国食品医薬品局（FDA）が新薬承認申請（NDA）を受理し、優先審査を付与したと発表しました。本申請は、ブルトン型チロシンキナーゼ（BTK）阻害薬による治療後に再発または難治性（R/R）マントル細胞リンパ腫（MCL）がみられる成人患者を対象とするものです。 BeOneのグローバル研究開発責任者を務めるライ・ワン博士は次のように述べています。「ソンロトクラックスは、画期的治療薬指定を受けてから優先審査が付与されるまで、非常に短期間のうちに進んでいます。このように急速に進展していることの背景には、データが強固であることに加えて、R/R MCL患者にとってニーズが切迫しているという事情があります。迅速で深く、持続的な奏効に加え、管理しやすい安全性プロファイルを示すソンロトクラックスは、当社の血液疾患領域に...

INCHEON, Corea del Sud--(BUSINESS WIRE)--La Commissione Europea (CE) ha approvato l'estensione di linea nell'Unione Europea (UE) per Omlyclo™ (omalizumab) di Celltrion, il primo e unico biosimilare di omalizumab in Europa, per la siringa preriempita (PFS) da 300 mg/2ml. La Commissione Europea (CE) ha approvato la soluzione iniettabile di Omlyclo™ da 75 mg/0,5ml e 150mg/1ml in siringa preriempita nel maggio 2024. Omlyclo™ è indicato nel trattamento di pazienti affetti da asma allergica, orticari...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation. Lenivia is built on a decade of s...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences: 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL...